The endogenous thrombin potential and the risk of venous thromboembolism

Thrombosis Research

Volumn 121, Issue 3, 2007, Pages 353-359

  Tripodi, Armando ^a   Martinelli, Ida ^a   Chantarangkul, Veena ^a   Battaglioli, Tullia ^a   Clerici, Marigrazia ^a   Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Laboratory testing; Screening; Thrombin generation; Thrombophilia

Indexed keywords

THROMBIN; THROMBOMODULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 37648999269     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.04.012     Document Type: Article

References (38)

1. Nordstrom M., Lindblad B., Berquist D., and Kjellstrom T. A prospective study of the incidence of deep vein thrombosis with a defined urban population. J Intern Med 232 (1992) 155-160
2. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., et al. A population based prospective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT study. Arch Intern Med 151 (1991) 933-938
3. Seligsohn U., and Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 344 (2001) 1222-1231
4. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 86 (2001) 395-403
5. Koster T., Rosendaal F.R., de Ronde H., Briet E., Vandenbroucke J.P., and Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
6. Rosendaal F.R., Koster T., Vandenbroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
7. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
8. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., and Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
9. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
10. Frezzato M., Tosetto A., and Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 143 (1996) 1257-1265
11. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346 (1995) 1575-1582
12. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
13. Martinelli I., Mannucci P.M., De Stefano V., Taioli E., Rossi V., Crosti F., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92 (1998) 2353-2358
14. Lindqvist P., Dahlback B., and Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 94 (1999) 595-599
15. Martinelli I., Taioli E., Bucciarelli P., Akhavan S., and Mannucci P.M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 19 (1999) 700-703
16. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., and Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 (2002) 791-795
17. Rosendaal F.R., Vessey M., Rumley A., Daly E., Woodward M., Helmerhorst F.M., et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 116 (2002) 851-854
18. Lensing A.W.A., and Prins M.H. Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis?. Thromb Haemost 82 (1999) 1564-1566
19. De Stefano V., Martinelli I., Mannucci P.M., Paciaroni K., Chiusolo P., Casorelli I., et al. The risk for recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
20. Simioni P., Prandoni P., Lensing A.W., Manfrin D., Tormene D., Gavasso S., et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96 (2000) 3329-3333
21. Agnelli G., et al., The Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Engl J Med 345 (2001) 165-169
22. Miles J.S., Miletich J.P., Goldhaber S.Z., Hennekens C.H., and Ridker P.M. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37 (2001) 215-218
23. Eichinger S., Weltermann A., Mannhalter C., Minar E., Bialonczyk C., Hirschl M., et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Int Med 162 (2002) 2357-2360
24. Salomon O., Steinberg D.M., Zivelin A., Gitel S., Dardik R., Rosenberg N., et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 19 (1999) 511-518
25. Emmerich J., Rosendaal F.R., Cattaneo M., Margaglione M., De Stefano V., Cumming T., et al. Combined effect of factor V Leiden and prothrombin 20210A and the risk of venous thromboembolism. Pooled analysis of 8 case control studies including 2310 cases and 3204 controls. Study group of pooled-analysis in venous thromboembolism. Thromb Haemost 86 (2001) 809-816
26. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
27. Brandt J.T., Triplett D.A., Alving B., and Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the ISTH. Thromb Haemost 74 (1995) 1185-1190
28. Chantarangkul V., Clerici M., Bressi A., Giesen P.L., and Tripodi A. Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hypo- or hyper-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma. Haematologica 88 (2003) 547-554
29. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 345 (1995) 152-155
30. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
31. Van Hylckama A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increases the risk of venous thrombosis. Blood 95 (2000) 3678-3682
32. Meijers J.C.M., Tekelenburg W.L.H., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of factor XI as a risk factor for venous thrombosis. New Eng J Med 342 (2000) 696-701
33. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briet E., and Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphism. The Leiden Thrombophilia Study (LETS). Thromb Haemost 71 (1994) 719-722
34. Tripodi A., Chantarangkul V., Martinelli I., Bucciarelli P., and Mannucci P.M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104 (2004) 3631-3634
35. Hron G., Eichinger S., Weltermann A., Quehenberger P., Halbmayer W.M., and Kyrle P.A. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 4 (2006) 752-756
36. Legnani C., Mattarozzi S., Cini M., Cosmi B., Favaretto E., and Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 134 (2006) 227-232
37. Bauer K.A. The thrombophilias: well defined risk factors with uncertain therapeutic implications. Ann Intern Med 135 (2001) 367-373
38. Esmon C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264 (1989) 4743-4746